Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s LLY tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.DataCompared with tirzepatide, Wegovy showed a significant 57% greater risk reduct ...

Core Insights - The 2025 ESC/EAS Dyslipidemia Guideline Update reaffirms high-dose icosapent ethyl (IPE) as a Class IIA recommended therapy for high-risk or very high-risk patients to reduce cardiovascular events based on the REDUCE-IT trial findings [1][14] Group 1: REDUCE-IT Trial Findings - Three sub-analyses from the REDUCE-IT trial demonstrate significant reductions in cardiovascular disease (CVD) risk and outcomes associated with IPE administration in patients with cardiovascular-kidney-metabolic (CKM) syndrome, stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride-rich lipoprotein cholesterol (TRL-C) levels [1][2] - IPE treatment showed a 44% relative risk reduction (RRR) for the primary composite endpoint in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², with a hazard ratio (HR) of 0.56 (95% CI 0.39, 0.79), P = 0.001, and an absolute risk reduction (ARR) of 11.2% [4][5] Group 2: Impact on Major Adverse Cardiovascular Events (MACE) - IPE treatment resulted in significant reductions in MACE across all quartiles of baseline ApoB and TRL-C concentrations, with HRs ranging from 0.72 to 0.80 for ApoB and from 0.74 to 0.68 for TRL-C, all with P ≤ 0.02 [8][9] Group 3: Hospitalization and Mortality Outcomes - IPE significantly reduced total hospitalizations (HR 0.91, 95% CI 0.84, 0.98, P=0.017) and increased the likelihood of surviving without hospitalization (odds ratio (OR) 1.12, 95% CI 1.02, 1.22, P=0.016) [12][13] Group 4: Clinical Recommendations - The ESC/EAS guidelines recommend high-dose IPE for patients with elevated triglyceride levels (135–499 mg/dL) despite statin therapy, emphasizing its role in reducing CVD events [14]